Solar stocks surge after Treasury tightens clean energy tax credit rules
Cryoport, Inc. (NASDAQ:CYRX), which has seen its stock surge over 31% in the past week despite being down 59% over the past year, recently witnessed a stock transaction involving its President and CEO, Jerrell Shelton. According to a recent SEC filing, Shelton sold 4,173 shares of Cryoport common stock on March 10, 2025, at an average price of $4.8791 per share. This transaction amounted to a total value of approximately $20,360.
Additionally, on March 9, 2025, Shelton converted 8,250 restricted stock rights into common shares. These restricted stock rights vested as part of a previously granted award and were converted on a one-for-one basis without any monetary exchange.
Following these transactions, Shelton holds 740,019 shares of Cryoport common stock. The share sale was conducted in accordance with the company’s policies to cover taxes due upon the vesting of restricted stock rights.
In other recent news, CryoPort reported its financial results for the fourth quarter of 2024, revealing a mixed performance. The company experienced a larger-than-expected loss per share, posting an EPS of -0.42, which missed the forecast of -0.29. However, CryoPort’s revenue exceeded expectations, reaching $59.53 million against the projected $58.64 million. The company also noted a significant improvement in its gross margin, which rose to 45.8% from 40.6% the previous year. Looking ahead, CryoPort has set a revenue guidance of $240-$250 million for 2025, with expectations of high 20% growth in commercial cell and gene therapy revenue.
Additionally, Jefferies analyst Matthew Stanton adjusted the price target for CryoPort stock, reducing it to $6.50 from the previous $8.00, while maintaining a Hold rating on the shares. Stanton highlighted the necessity for greater clarity regarding the company’s growth trajectory and margin improvement strategy. Despite the challenges, CryoPort is targeting positive adjusted EBITDA in 2025, driven by continued growth in life sciences services and new product launches. The company also launched new products and signed initial contracts for IntegraCell, aiming to diversify its revenue streams.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.